#None #New York #Pomerantz LLP #Sarepta Therapeutics #ELEVIDYS

Introduction

In a crucial development for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Pomerantz LLP has begun an investigation surrounding potential claims of securities fraud related to the company. This scrutiny arises amidst alarming events tied to Sarepta's Duchenne muscular dystrophy treatment, ELEVIDYS.

Background on Sarepta Therapeutics

Sarepta Therapeutics specializes in developing gene therapies for serious medical conditions, particularly muscle-related diseases. The company gained attention with its drug, ELEVIDYS, which was touted as a breakthrough in treating Duchenne muscular dystrophy. However, recent reports have raised questions about its safety, leading to significant repercussions for the company and its investors.

Investigation Details

Pomerantz LLP is reaching out to investors to discuss the implications of the recent events involving Sarepta. The firm aims to determine whether the company and its executives participated in any fraudulent actions that misled investors about the safety and efficacy of ELEVIDYS. This comes after Sarepta disclosed the tragic death of a young man who had undergone treatment with this drug, which led to acute liver failure.

On March 18, 2025, this unfortunate news caused Sarepta's stock to plummet by approximately 27.44%, signaling the market's reaction to the grave implications of such an incident.

Further Developments

Compounding these troubles, on June 16, 2025, Sarepta announced another fatality linked to acute liver failure connected to the use of ELEVIDYS. Following this revelation, the company suspended its ongoing clinical trials and halted distribution of the drug for patients who could no longer walk. Consequently, the stock price dropped again, this time by over 42%, illustrating a loss of investor confidence and heightening concerns of mismanagement.

Pomerantz LLP’s Mission

Pomerantz LLP has established itself as a leader in corporate and securities law, known for advocating on behalf of investors who have suffered from corporate misconduct. Founded by the late Abraham L. Pomerantz, the firm has pursued justice for victims of inaccuracies in corporate disclosures, and its latest investigation into Sarepta Therapeutics underscores its commitment to holding companies accountable.

The firm has a strong history of achieving significant settlements in securities class action lawsuits and aims to protect the rights of Sarepta's investors during this troubling chapter.

Conclusion

Investors of Sarepta Therapeutics are advised to reach out to Pomerantz LLP for guidance. For those affected by the adverse developments linked to ELEVIDYS, participating in this investigation could be a vital step towards pursuing justice and potentially recovering losses incurred. As the investigation unfolds further details are expected that could shed light on the company’s practices leading to tragic outcomes. Investors are urged to stay informed and vigilant about their rights.

For more information, contact Danielle Peyton at Pomerantz LLP directly.

Contact Information

• - Danielle Peyton
• - Phone: 646-581-9980 ext. 7980
• - Email: [email protected]

Stay tuned for updates as this investigation progresses, as it will have significant implications for both Sarepta and its investors.